Radiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite

British Journal of Radiology

Volumn 85, Issue 1017, 2012, Pages 1279-1286

  Uzan, Julien ^a   Nahum, A E ^a  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CASE REPORT; CELL PROLIFERATION; CLONOGENESIS; COMPUTER PROGRAM; DOSE RESPONSE; ESOPHAGITIS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MATHEMATICAL MODEL; METASTASIS; PRESCRIPTION; PROBABILITY; PROSTATE CARCINOMA; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME;

COMPUTER SIMULATION; DOSE FRACTIONATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOFTWARE;

EID: 84866117640     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/20476567     Document Type: Article

References (49)

1. Kong FM, Hayman JA, Griffith KA, Kalemkerian GP, Arenberg D, Lyons S, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 2006;65:1075-86.
2. Coote JH, Wylie JP, Cowan RA, Logue JP, Swindell R, Livsey JE. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys 2009;74:1121-7.
3. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74.
4. Zaider M, Amols HI. A little to a lot or a lot to a little: is NTCP always minimized in multiport therapy? Int J Radiat Oncol Biol Phys 1998;41:945-50.
5. Engelsman, M, Remeijer, P, van Herk M, Lebesque JV, Mijnheer B, Damen EMF. Field size reduction enables Iso-NTCP escalation of tumor control probability for irradiation of lung tumours. Int J Radiat Oncol Biol Phys 2001;51:1290-8.
6. Nahum A, Kutcher G. Biological evaluation of treatment plans. In: Mayles P, Nahum AE, Rosenwald JC, eds. Handbook of radiotherapy physics theory and practice. Boca Raton, FL: Taylor & Francis; 2007. pp. 731-71.
7. Dale R, Jones B. Radiobiological modeling in radiation oncology. London, UK: British Institute of Radiology; 2007.
8. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985;8:S13-19.
9. Lyman JT, Wolbarst AB. Optimisation of radiation therapy. III. A method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys 1987;13:103-9.
10. Källman P, Agren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol 1992;62:249-62.
11. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985;58:515-28.
12. Zaider M, Minerbo GN. Tumour control probability: a formulation applicable to any temporal protocol of dose delivery. Phys Med Biol 2000;45:279-93.
13. Seppenwoolde Y, Lebesque JV, de Jaeger K, Belderbos JS, Boersma LJ, Schilstra C, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2003;55:724-35.
14. Semenenko VA, Li XA. Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. Phys Med Biol 2008;53:737-55.
15. Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK, et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dosevolume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys 2010;76(Suppl. 3):S155-60.
16. Sanchez-Nieto B, Nahum AE. BIOPLAN: software for the biological evaluation of radiotherapy treatment plans. Med Dosim 2000;25:71-6.
17. El Naqa I, Suneja G, Lindsay PE, et al. Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships. Phys Med Biol 2006;51:5719-35.
18. Gayou O, Parda DS, Miften M. EUCLID: an outcome analysis tool for high-dimensional clinical studies. Phys Med Biol 2007;52:1705-19.
19. Warkentin B, Stavrev P, Stavreva N, Field C, Fallone BG. A TCP-NTCP estimation module using DVHs and known radiobiological models and parameter sets. J Appl Clin Med Phys 2004;5:50-63.
20. Semenenko VA, Reitz B, Day E, Qi XS, Miften M, Li XA. Evaluation of a commercial biologically based IMRT treatment planning system. Med Phys 2008;35:5851-60.
21. Nahum AE, Tait DM. Maximising local control by customized dose prescription for pelvic tumours. In: Breit A, ed. Advanced radiation therapy: tumour response monitoring and treatment planning; proceedings of the ART91 symposium, Munich, April 1991. Berlin, Germany: Springer-Verlag; 1992. pp. 425-31.
22. Sanchez-Nieto B, Nahum AE, Dearnaley DP. Individualization of dose prescription based on normal-tissue dose-volume and radiosensitivity data. Int J Radiat Oncol Biol Phys 2001;49:487-99.
23. van Baardwijk A, Bosmans G, Bentzen SM, Boersma L, Dekker A, Wanders R, et al. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. Int J Radiat Oncol Biol Phys 2008;71:1103-10.
24. Song DY, Benedict SH, Cardinale RM, Chung TD, Chang MG, Schmidt-Ullrich RK. Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits. Am J Clin Oncol 2005;28:591-6.
25. Brent RP, ed. Algorithms for minimization without derivatives. Englewood Cliffs, NJ: Prentice-Hall; 1973.
26. Nahum AE, Sanchez-Nieto B. Tumour control probability modelling: basic principles and applications in treatment planning. Phys Med 2001;17(Suppl. 2):13-23.
27. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 1989;16:1623-30.
28. Wheldon TE, Deehan C, Wheldon EG, Barrett A. The linearquadratic transformation of dose-volume histograms in fractionated radiotherapy. Radiother Oncol 1998;46:285-95.
29. Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med Phys 1999;26:1100.
30. Luxton G, Keall PJ, King CR. A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD). Phys Med Biol 2008;53:23-36.
31. Lea DE, Catcheside DG. The mechanism of the induction by radiation of chromosome aberrations in Tradescantia. J Genet 1942;44:216-45.
32. Bentzen SM, Saunders MI, Dische S. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome. Clin Oncol (R Coll Radiol) 2002;14:372-81.
33. Fenwick JD, Nahum AE, Malik ZI, Eswar CV, Hatton MQ, Laurence VM, et al. Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement. Clin Oncol (R Coll Radiol) 2009;21:343-60.
34. Admiraal MA, Schuring D, Hurkmans CW. Dose calculations accounting for breathing motion in stereotactic lung radiotherapy based on 4D-CT and the internal target volume. Radiother Oncol 2008;86:55-60.
35. Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 2003;57:391-401.
36. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87.
37. Nahum AE, Uzan J, Jain P, Malik ZI, Fenwick JD, Baker C. Quantitative tumour control predictions for the radiotherapy of non-small-cell lung tumours. Poster at the 2011 Joint AAPM/COMP Meeting; Vancouver, BC; 31 July-4 August 2011.
38. Rancati T, Fiorino C, Valvassori V, et al. Late rectal bleeding after conformal radiotherapy for prostate cancer: NTCP modeling. Radiother Oncol 2008;88:S332-3.
39. Clifton Ling C, Gerweck LE, Zaider M, Yorke E. Dose-rate effects in external beam radiotherapy redux. Radiother Oncol 2010;95:261-8.
40. Joiner MC, Bentzen SM. Time-dose relationships: the linearquadratic approach. In: Steel GC, ed. Basic clinical radiobiology. 3rd edn. London, UK: Edward Arnold; 1993. pp. 55-64.
41. Schulz CA, Harari PM, Mehta MP. Multiple daily fractionation radiotherapy schedules in lung cancer. Curr Oncol Rep 2001;3:179-84.
42. Din OS, Lester J, Cameron A, Ironside J, Gee A, Falk S, et al. Routine use of continuous, hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer: a five-center experience. Int J Radiat Oncol Biol Phys 2008;72:716-22.
43. Wu J, Li H, Shekhar R, Suntharalingam M, D'Souza W. An evaluation of planning techniques for stereotactic body radiation therapy in lung tumors. Radiother Oncol 2008;87:35-43.
44. Lim DH, Yi BY, Mirmiran A, Dhople A, Suntharalingam M, D'Souza WD. Optimal beam arrangement for stereotactic body radiation therapy delivery in lung tumors. Acta Oncol 2010;49:219-24.
45. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, Van der Heide UA, Schuring D, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol 2009;4:1.
46. Witte MG, van der Geer J, Schneider C, Lebesque JV, Alber M, van Herk M. IMRT optimization including random and systematic geometric errors based on the expectation of TCP and NTCP. Med Phys 2007;34:3544-55.
47. Uzan J, Nahum AE, Mayles P, Syndikus I. Radiobiologically-based inverse optimisation of IMRT plans for prostate cancer. Radiother Oncol 2010;96(Suppl. 1):S178.
48. Schilstra C, Meertens H. Calculation of the uncertainty in complication probability for various dose-response models applied to the parotid gland. Int J Radiat Oncol Biol Phys 2001;50:147-58.
49. alglib.net [homepage on the internet]. Nizhny Novgorod, Russian Federation: ALGLIB Project [cited 15 November 2011]. Available from: www.alglib.net